Navigation Links
Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
Date:11/4/2011

TUSTIN, Calif., Nov. 4, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced that all six proxy resolutions passed at a special meeting of shareholders today.

The Company's proxy statement was filed with the Securities and Exchange Commission on October 14, 2011 is available at www.sec.gov and on the Company's web site:  www.radient-pharma.com Radient Pharmaceuticals also announced that it has retained E & E Communications, Laguna Hills, California, and its principal, Paul Knopick, to assist with its public and investor relations program.

The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $165,000*

*Approximate amount as of November 2, 2011Common Shares Outstanding:  647 million*

*Approximate number as of November 2, 2011.

  750 million shares authorized.Outstanding Warrants & Options:  110 million*

*Approximate number as of November 2, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Paul Knopick
E & E Communications
949.707.5365
pknopick@eandecommunications.com


'/>"/>

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
2. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a spin-out of the ... has truly taken their cancer research out of this world. On April 22, ... Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by the ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Therapeutics Summit ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September ... conference to learn about the latest advances in the treatment of various types ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):